DOWNLOAD GP CME 2010 PROCEEDINGS BOOKLET (18mb PDF)

12
OxyContin
®
tablets
When osteoarthritis
oa
pain is controlled,
o
life begins.
1
OxyContin ® tablets provide long-acting
relief from moderate to severe chronic
osteoarthritis pain. 1,2 *
FULLY FUNDED
PHARMACEUTICAL SCHEDULE
OxyContin ® tablets should be used as part of a multi-modal pain management plan, not in isolation.
*CONTROLLED DRUG B3 – For the management of moderate to severe chronic pain unresponsive to non-narcotic analgesia.
OxyContin ® tablets – oxycodone hydrochloride
Presentation Oxycodone hydrochloride 5mg, 10mg, 20mg, 40mg, 80mg controlled release tablets is a Controlled Drug Class B3. Indication The management of
moderate to severe chronic pain unresponsive to non-narcotic analgesia. Dosage and Administration Must be swallowed whole and not broken, chewed
or crushed. Taking broken, chewed or crushed OxyContin ® tablets could lead to the rapid release and absorption of a potentially toxic dose of
oxycodone. Alcohol should be avoided while the patient is being treated with OxyContin ® tablets. Adults, elderly and children over 12 years: Dose at 12-hourly
intervals. Usual starting dose (opioid-naïve patients or patients with severe pain uncontrolled by weaker opioids): one OxyContin ® 10mg tablet 12-hourly. Patients
with renal or hepatic impairment: one OxyContin ® 5mg tablet 12-hourly. Titrate carefully (once a day if required) to achieve pain relief. 10mg oral oxycodone is
equivalent to 20mg oral morphine. OxyContin ® 80mg tablets should only be used in opioid-tolerant patients. Children: Not recommended in children under
12 years of age. Contraindications Hypersensitivity to opioids or to any constituents of OxyContin ® tablets, acute respiratory depression, cor pulmonale, cardiac
arrhythmias, acute asthma or other obstructive airways disease, paralytic ileus, suspected surgical abdomen, severe hepatic impairment, delayed gastric emptying,
acute alcoholism, brain tumour, increased cerebrospinal or intracranial pressure, head injury, severe CNS depression, convulsive disorders, delirium tremens, hypercarbia,
concurrent administration of monoamine oxidase inhibitors (MAOIs) or within 2 weeks of discontinuation of their use, pregnancy. Not recommended for pre-operative
use or for the first 24 hours post-operatively. Warnings and Precautions The major risk of opioid excess is respiratory depression. Use with caution in patients
with hypothyroidism (may need to reduce dose), debilitated elderly or infirm patients, opioid dependence, hypotension, hypovolaemia, diseases of the biliary tract,
pancreatitis, inflammatory bowel disorders, prostatic hypertrophy, adrenocortical insufficiency (Addison’s disease), toxic psychosis, chronic pulmonary, renal or hepatic
disease, myxoedema, following abdominal surgery, chronic, non-malignant pain, a prior history of substance abuse. Discontinue use if paralytic ileus is suspected or
occurs. As with other opioids, tolerance and physical dependence tend to develop upon repeated administration of oxycodone. There is potential for abuse of the
medicine and for development of strong psychological dependence. OxyContin ® tablets should therefore be prescribed and handled with a high degree of caution
appropriate to the use of a medicine with strong abuse potential. Not recommended in pregnancy (Category C), lactation. Tolerance and physical dependence tend to
develop upon repeated administration. Withdraw gradually. Parenteral venous injection of the tablet constituents may be fatal. May affect driving or operating machinery.
Do not use in immediate pre-operative period, or within 24 hours of cordotomy or other pain-relieving surgery. Special Risk Groups: Reduce dosage in elderly, debilitated
patients and in patients with renal impairment or hepatic impairment (1/3 to 1/2 of usual starting dose). Adverse Effects Adverse medicine reactions are typical of full
opioid agonists. Gastrointestinal disorders abdominal pain, constipation, diarrhoea, nausea, dry mouth, dyspepsia, vomiting; General disorders asthenia, chills;
Hepatobiliary disorders cholestasis, increased hepatic enzymes; Metabolic and nutritional disorders anorexia; Nervous System disorders dizziness, headache,
somnolence; Psychiatric disorders anxiety, confusional state, insomnia, nervousness, thinking abnormal; Respiratory, Thoracic and Mediastinal disorders dyspnoea,
respiratory depression; Skin and Subcutaneous Tissue disorders hyperhidrosis, pruritus, rash. Interactions Anticholinergic agents, antihypertensive agents, CNS
depressants (including sedatives or hypnotics, general anaesthetics, phenothiazines, other tranquillisers, alcohol, other opioids and neuroleptic medicines, etc), coumarin
derivatives, metoclopramide, monoamine oxidase inhibitors (MAOIs), neuromuscular blocking agents, opioid agonist analgesics (including morphine, pethidine), opioid
agonist-antagonist analgesics (including pentazocine, butorphanol, buprenorphine). Metabolic interactions with medicines that involve the cytochrome P450 enzyme
system (CYP3A4, CYP2D6). Pharmaceutical Schedule Fully funded. Standard prescription charge applies. Distributed on behalf of Mundipharma New Zealand
Limited by: Pharmaco (NZ) Ltd, P O Box 4079, AUCKLAND Ph: (09) 377-3336 Toll Free (Medical Enquiries): 0800 773 310 Fax: (09) 307 1307 Data Sheet: 21 May 2010
®: OXYCONTIN is a Registered Trademark.
For further information and prior to prescribing please refer to the manufacturer’s Data Sheet available on the Medsafe website www.medsafe.govt.nz
ORBIS NZ-0091 DA1211AY MP5518 May 2011
References 1. Roth SH et al. Around-the-clock, controlled-release oxycodone
therapy for osteoarthritis-related pain. Arch Intern Med 2000,160:853-860.
2. OxyContin ® tablets Data Sheet, May 2010.